Why Is Blue Owl Capital Corporation (OBDC) Down 3% Since Last Earnings Report?

A month has gone by since the last earnings report for Blue Owl Capital Corporation (OBDC). Shares have lost about 3% in that time frame, outperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Blue Owl Capital Corporation due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.VGM ScoresCurrently, Blue Owl Capital Corporation has an average Growth Score of C, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Blue Owl Capital Corporation has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerBlue Owl Capital Corporation belongs to the Zacks Financial - Miscellaneous Services industry. Another stock from the same industry, Royalty Pharma (RPRX), has gained 0.5% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.Royalty Pharma reported revenues of $742 million in the last reported quarter, representing a year-over-year change of +0.8%. EPS of $1.15 for the same period compares with $1.15 a year ago.Royalty Pharma is expected to post earnings of $1.02 per share for the current quarter, representing a year-over-year change of +4.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.8%.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Royalty Pharma. Also, the stock has a VGM Score of D.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Blue Owl Capital Corporation (OBDC): Free Stock Analysis Report Royalty Pharma PLC (RPRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks